SCHEMBL2269880

SCHEMBL2269880

COC(=O)c1ccc(Sc2ccccc2)cc1NC(=O)c1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.60
HSD17B10 Q99714 2/20 0.60
MAPK1 P28482 2/20 0.60
MAPT P10636 4/20 0.52
TDP1 Q9NUW8 3/20 0.52
ALDH1A1 P00352 3/20 0.52
TSHR P16473 2/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C19 P33261 1/20 0.51
APOBEC3A P31941 1/20 0.50
APOBEC3G Q9HC16 1/20 0.50
HPGD P15428 4/20 0.49
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
ALOX12 P18054 1/20 0.49
PKM P14618 1/20 0.49
GRIK1 P39086 1/20 0.49
GAA P10253 2/20 0.48
LMNA P02545 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2270296 0.86 TDP1 (0.62) MAPTTDP1ALDH1A1MEN1KMT2A
SCHEMBL2273993 0.83 KDM4E (0.55) KDM4EHSD17B10MAPK1MAPTALDH1A1
SCHEMBL2275077 0.81 KDM4E (0.66) KDM4EHSD17B10MAPK1MAPTTDP1
SCHEMBL2276099 0.81 KDM4E (0.66) KDM4EHSD17B10MAPK1MAPTTDP1
SCHEMBL2274042 0.80 KDM4E (0.57) KDM4EHSD17B10MAPK1MAPTALDH1A1
SCHEMBL2269238 0.80 KDM4E (0.68) KDM4EHSD17B10MAPK1MAPTALDH1A1
SCHEMBL14428376 0.80 KDM4E (0.64) KDM4EHSD17B10MAPK1MAPTTDP1
SCHEMBL2271167 0.80 KDM4E (0.64) KDM4EHSD17B10MAPK1MAPTTDP1
SCHEMBL2275624 0.80 KDM4E (0.64) KDM4EHSD17B10MAPK1MAPTTDP1
SCHEMBL14428397 0.78 MAPT (0.55) MAPK1MAPTTDP1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 KDM4E 1257/4885HSD17B10 566/4885MAPK1 168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.